Your browser doesn't support javascript.
loading
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang, Yoon-Koo; Chen, Li-Tzong; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Chung, Hyun Cheol; Lee, Keun-Wook; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Chung, Ik-Joo; Yamaguchi, Kensei; Kato, Ken; Sym, Sun Jin; Kadowaki, Shigenori; Tsuji, Kunihiro; Chen, Jen-Shi; Bai, Li-Yuan; Oh, Sung-Yong; Choda, Yasuhiro; Yasui, Hisateru; Takeuchi, Kentaro; Hirashima, Yoshinori; Hagihara, Shunsuke; Boku, Narikazu.
Afiliação
  • Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Chen LT; National Institute of Cancer Research, National Health Research Institutes, and National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan; Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Ryu MH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Oh DY; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea; Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Korea.
  • Oh SC; Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea.
  • Chung HC; Division of Medical Oncology, Yonsei Cancer Center, Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
  • Lee KW; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
  • Omori T; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
  • Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Sakuramoto S; Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Chung IJ; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun, South Korea.
  • Yamaguchi K; Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kato K; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Sym SJ; Department of Internal Medicine, Division of Medical Oncology, Gachon University Gil Medical Center, Incheon, South Korea.
  • Kadowaki S; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Tsuji K; Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
  • Chen JS; Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
  • Bai LY; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, and China Medical University, Taichung, Taiwan.
  • Oh SY; Department of Hemato-Oncology, Dong-a University Hospital, Busan, South Korea.
  • Choda Y; Department of Surgery, Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Yasui H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan.
  • Takeuchi K; Department of Oncology Clinical Development Planning, Ono Pharmaceutical, Osaka, Japan.
  • Hirashima Y; Department of Oncology Clinical Development Planning, Ono Pharmaceutical, Osaka, Japan.
  • Hagihara S; Department of Statistical Analysis, Ono Pharmaceutical, Osaka, Japan.
  • Boku N; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Electronic address: nboku@ncc.go.jp.
Lancet Oncol ; 23(2): 234-247, 2022 02.
Article em En | MEDLINE | ID: mdl-35030335
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Junção Esofagogástrica / Nivolumabe / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Coréia do Sul
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Junção Esofagogástrica / Nivolumabe / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Coréia do Sul